-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
The well-known magazine Lancet recently published a review article focusing on the long-term follow-up of patients with new coronary pneumonia after recovery and discharge.
As of early January 2021, the new coronary pneumonia caused by severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) has caused more than 83 million confirmed cases and more than 1.
Coronavirus disease
The research published by Huang Chaolin's team in The Lancet is realistic and timely.
The Lancet diagnosed thrombosis in patients with severe new coronary pneumonia during the hospitalization, and then will face cognitive, mental health or physical function impairment, which is far beyond the scope of their discharge .
Long-term follow-up of recovered patients with COVID-19 leave a message here